Companies /Healthcare
AdaptHealth Corp
NASDAQ: AHCO Medical Devices
$7.31
▲ $1.03 (+16.40%) today
Markets closed · 5:00pm ET

AdaptHealth (AHCO) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
0%
EPS beat rate
−585.62%
Avg. EPS surprise
Consecutive EPS misses
AHCO vs Market · 30-day return after each reportAHCOS&P 500
0%+20%+0.6%+7.2%Q1 25−5.9%+3.1%Q2 25−11.7%+1.6%Q3 25+28.9%−6.2%Q4 25−15.8%+1.9%Q1 26−4.3%+0.2%Q2 26
0%+20%Q1 25Q3 25Q1 26
AHCO EPS Trend · estimate vs actualEstimateActual
$-1.00$-0.50$0.00$0.04$-0.05Q1 25$0.16$0.10Q2 25$0.24$0.16Q3 25$0.34$-0.76Q4 25$0.01$-0.12Q1 26$0.17$-0.99Q2 26$-0.06$-1.13Q3 26
$-1.00$-0.50$0.00Q1 25Q3 25Q1 26Q3 26
AHCO Revenue Trend · estimate vs actualEstimateActual
$0$300.0M$600.0M$900.0M$764.8M$777.9MQ1 25$803.8M$800.4MQ2 25$799.3M$820.3MQ3 25$831.6M$846.3MQ4 25$796.6M$819.8MQ1 26$846.8M$740.3MQ2 26$725.9M$745.6MQ3 26
$0$300.0M$600.0M$900.0MQ1 25Q3 25Q1 26Q3 26

How Often Does AdaptHealth Beat Earnings Estimates?

AdaptHealth beat EPS estimates in 0 of its last 7 reported quarters, and has missed 7 quarters in a row.

AHCO quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Includes a $184.8 million pre-tax non-cash goodwill impairment (Respiratory Health and Wellness at Home reporting units), partially offset by a $12.0 million pre-tax gain on deconsolidation of the former eCommerce subsidiary; also includes $14.3 million net income from discontinued operations (Diabetes Health). Diluted loss per share from continuing operations was $(1.23). $-1.13 est. $-0.06 −1,665.62% $745.6M est. $725.9M +2.73%
Q2 2026 $-0.99 est. $0.17 −689.29% $740.3M est. $846.8M −12.57%
Q1 2026 $-0.12 est. $0.01 −1,125.64% $819.8M est. $796.6M +2.91%
Q4 2025 $-0.76 est. $0.34 −323.86% $846.3M est. $831.6M +1.77%
Q3 2025 $0.16 est. $0.24 −33.14% $820.3M est. $799.3M +2.63%
Q2 2025 $0.10 est. $0.16 −36.79% $800.4M est. $803.8M −0.43%
Q1 2025 $-0.05 est. $0.04 −225.00% $777.9M est. $764.8M +1.71%

Figures from SEC filings and company reports. Not investment advice.